[HTML][HTML] Biosimilars in inflammatory bowel disease: facts and fears of extrapolation
S Ben-Horin, NV Casteele, S Schreiber… - Clinical Gastroenterology …, 2016 - Elsevier
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, NV Casteele… - … and hepatology: the …, 2016 - pubmed.ncbi.nlm.nih.gov
Biologic drugs such as infliximab and other anti-tumor necrosis factor monoclonal antibodies
have transformed the treatment of immune-mediated inflammatory conditions such as …
have transformed the treatment of immune-mediated inflammatory conditions such as …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
S Ben-Horin, V Casteele, S Schreiber… - … and Hepatology: the …, 2016 - europepmc.org
Biologic drugs such as infliximab and other anti-tumor necrosis factor monoclonal antibodies
have transformed the treatment of immune-mediated inflammatory conditions such as …
have transformed the treatment of immune-mediated inflammatory conditions such as …
[PDF][PDF] PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
S Ben-Horin, NV Casteele, S Schreiber… - Clinical …, 2016 - core.ac.uk
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
[HTML][HTML] Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, NV Casteele, S Schreiber… - Clinical …, 2016 - cghjournal.org
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, NV Casteele, S Schreiber… - Clinical Gastroenterology …, 2016 - infona.pl
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
[PDF][PDF] Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, NV Casteele, S Schreiber, PL Lakatos - 2016 - repo.lib.semmelweis.hu
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, N Vande Casteele… - Clinical …, 2016 - oceanrep.geomar.de
Biologic drugs such as infliximab and other anti-tumor necrosis factor monoclonal antibodies
have transformed the treatment of immune-mediated inflammatory conditions such as …
have transformed the treatment of immune-mediated inflammatory conditions such as …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, NV Casteele, S Schreiber… - Clinical Gastroenterology …, 2016 - infona.pl
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
antibodies have transformed the treatment of immune-mediated inflammatory conditions …
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
S Ben-Horin, N Vande Casteele… - Clinical …, 2016 - oceanrep.geomar.de
Biologic drugs such as infliximab and other anti-tumor necrosis factor monoclonal antibodies
have transformed the treatment of immune-mediated inflammatory conditions such as …
have transformed the treatment of immune-mediated inflammatory conditions such as …